3-tigloyloxy-6-propionyloxytropane



Compound IDCDAMM02925
Common name3-tigloyloxy-6-propionyloxytropane
IUPAC name(8-methyl-6-propanoyloxy-8-azabicyclo[3.2.1]octan-3-yl) 2-methylbut-2-enoate
Molecular formulaC16H25NO4

Experimental data

Retention time17.49
Adduct[2M+Na]+
Actual mz613.342
Theoretical mz613.345
Error4.76
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.9972

Identifiers and class information

Inchi keyAUZMUMNBZCSKGT-BJMVGYQFSA-N
SmilesO=C(OC1CC2N(C)C(C1)C(OC(=O)CC)C2)C(=CC)C
SuperclassAlkaloids and derivatives
ClassTropane alkaloids

Plant source

  • Clitoria ternatea L.

    • Pharmacokinetic properties

    Number of descriptor values(#stars)0
    Number of non-conjugated amine groups (#amine)1
    Number of amidine and guanidine groups (#amidine)0
    Number of carboxylic acid groups (#acid)0
    Number of non-conjugated amide groups (#amide)0
    Number of rotatable bonds (#rotor)4
    Number of reactive functional groups (#rtvFG)2
    Predicted central nervous system activity (CNS)1
    Molecular weight (mol_MW)295.378
    Computed dipole moment(dipole)4.563
    Total solvent accessible surface area (SASA)575.598
    Hydrophobic component of SASA (FOSA)501.511
    Hydrophilic component of SASA (FISA)62.701
    Pie component of the SASA (PISA)11.386
    Weakly polar component of the SASA (WPSA)0
    Total solvent accesible volume (volume)1034.91
    Number of hydrogen bond donors (donorHB)0
    Number of hydrogen bond acceptors (accptHB)6
    Free energy of solvation of dipole (dip^2/V)0.0201179
    Index of cohesive interaction in solids (ACxDN^.5/SA)0
    Globularity descriptor (glob)0.859634
    Predicted polarizability in cubic angstroms (QPpolrz)32.803
    Predicted hexadecane/gas partition coefficient (QPlogPC16)8.389
    Predicted octanol/gas partition coefficient (QPlogPoct)13.559
    Predicted water/gas partition coefficient (QPlogPw)6.636
    Predicted octanol/water partition coefficient (QPlogPo/w)2.177
    Predicted aqueous solubility (QPlogS)-2.112
    Conformation-independent predicted aqueous solubility (CIQPlogS)-1.541
    Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.584
    Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)628.358
    Predicted brain/blood partition coefficient (QPlogBB)0.155
    Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)331.219
    Predicted skin permeability, log Kp (QPlogKp)-4.314
    PM3 calculated ionization potential (IP(ev))9.491
    PM3 calculated electron affinity (EA(eV))-0.045
    Number of likely metabolic reactions (#metab)4
    Prediction of binding to human serum albumin (QPlogKhsa)-0.153
    Predicted qualitative human oral absorption (HumanOralAbsorption)3
    Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)89.776
    Solvent-accessible surface area of fluorine atoms (SAFluorine)0
    Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
    Van der Waals surface area (PSA)70.167
    Number of nitrogen and oxygen atoms (#NandO)5
    Number of violations of Lipinski’s rule of five (RuleOfFive)0
    Number of violations of Jorgensen’s rule of three (RuleOfThree)0

    Compound-target network

    Cytoscape Graph

    Protein targets associated with phytocompound

    Uniprot ID Gene name Target name TTD_ID Prediction source
    P08173CHRM4Muscarinic acetylcholine receptor M4T20709SwissTargetPrediction
    P11229CHRM1Muscarinic acetylcholine receptor M1T28893SwissTargetPrediction
    P20309CHRM3Muscarinic acetylcholine receptor M3T67684SwissTargetPrediction
    P08172CHRM2Muscarinic acetylcholine receptor M2T46185SwissTargetPrediction

    Target associated diseases

    TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
    T20709DI0037Asthma[ICD-11: CA23]P08173CHRM4
    T20709DI0141Eye anterior segment structural developmental anomaly[ICD-11: LA11]P08173CHRM4
    T20709DI0166Glaucoma[ICD-11: 9C61]P08173CHRM4
    T20709DI0293Nausea/vomiting[ICD-11: MD90]P08173CHRM4
    T20709DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08173CHRM4
    T28893DI0001Abdominal pelvic pain[ICD-11: MD81]P11229CHRM1
    T28893DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P11229CHRM1
    T28893DI0101Corneal disease[ICD-11: 9A76-9A78]P11229CHRM1
    T28893DI0129Dystonic disorder[ICD-11: 8A02]P11229CHRM1
    T28893DI0154Functional bladder disorder[ICD-11: GC50]P11229CHRM1
    T28893DI0157Gastric ulcer[ICD-11: DA60]P11229CHRM1
    T28893DI0166Glaucoma[ICD-11: 9C61]P11229CHRM1
    T28893DI0186Hyperhidrosis[ICD-11: EE00]P11229CHRM1
    T28893DI0218Irritable bowel syndrome[ICD-11: DD91]P11229CHRM1
    T28893DI0331Parkinsonism[ICD-11: 8A00]P11229CHRM1
    T28893DI0333Peptic ulcer[ICD-11: DA61]P11229CHRM1
    T28893DI0371Sebaceous gland disorder[ICD-11: ED91]P11229CHRM1
    T67684DI0037Asthma[ICD-11: CA23]P20309CHRM3
    T67684DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P20309CHRM3
    T67684DI0154Functional bladder disorder[ICD-11: GC50]P20309CHRM3
    T67684DI0166Glaucoma[ICD-11: 9C61]P20309CHRM3
    T67684DI0293Nausea/vomiting[ICD-11: MD90]P20309CHRM3
    T67684DI0333Peptic ulcer[ICD-11: DA61]P20309CHRM3
    T67684DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P20309CHRM3
    T67684DI0371Sebaceous gland disorder[ICD-11: ED91]P20309CHRM3
    T67684DI0382Sjogren syndrome[ICD-11: 4A43]P20309CHRM3
    T67684DI0411Tonus and reflex abnormality[ICD-11: MB47]P20309CHRM3
    T46185DI0037Asthma[ICD-11: CA23]P08172CHRM2
    T46185DI0166Glaucoma[ICD-11: 9C61]P08172CHRM2
    T46185DI0278Muscle disorder[ICD-11: FB32-FB3Z]P08172CHRM2
    T46185DI0333Peptic ulcer[ICD-11: DA61]P08172CHRM2
    T46185DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08172CHRM2
    T46185DI0371Sebaceous gland disorder[ICD-11: ED91]P08172CHRM2

    Copyright © 2025